Evaluation of transplantation of mesenchymal cells in acute myocardial infarction

It has been studied in the pilot clinical research the effect of systemic (intravenous) transplantation of mesenchymal stem cells (MSC) of a bone marrow to 20 patients with an acute myocardial infarction with lifting segment of ST (STEMI) carried out in the first 2 hours by percutaneous coronary intervention (PCI) with stenting infarct related artery and the common course of drug therapy. It has been shown that the transplantation of MSCs had not caused any complications (allergic reactions, hazardous to health arrhythmias, embolism and heavy frustration of hemodynamic) and had not lead to condition deterioration afterwards. In the first 3-6 months after systemic transplantation of MSCs to the patients’ heart contractive activity has been advanced which was clinically proved in the reduction of the heart failure level degree of expressiveness of warm insufficiency.